Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 16/20 | 0.64 |
| ▸ | CCR5 | P51681 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14945890 | 0.90 | CCR2 (0.66) | CCR2CCR5LMNAKCNH2 | |
| SCHEMBL14945892 | 0.90 | CCR2 (0.66) | CCR2CCR5LMNAKCNH2 | |
| SCHEMBL14945893 | 0.90 | CCR2 (0.66) | CCR2CCR5LMNAKCNH2 | |
| SCHEMBL14945868 | 0.89 | CCR2 (0.78) | CCR2CCR5KCNH2 | |
| SCHEMBL14945866 | 0.89 | CCR2 (0.78) | CCR2CCR5KCNH2 | |
| SCHEMBL14945832 | 0.89 | CCR2 (0.78) | CCR2CCR5KCNH2 | |
| SCHEMBL15081442 | 0.88 | CCR2 (0.75) | CCR2CCR5KCNH2 | |
| SCHEMBL12184078 | 0.88 | CCR2 (0.76) | CCR2CCR5LMNA | |
| SCHEMBL14945901 | 0.88 | CCR2 (0.66) | CCR2CCR5KCNH2 | |
| SCHEMBL20976573 | 0.86 | CCR2 (0.62) | CCR2CCR5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2569298-B1 | NOVEL CCR2 RECEPTOR ANTAGONISTS, METHOD FOR PRODUCING THE SAME, AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2015-11-25 | — | — | EP | disclosed |
| US-8877745-B2 | CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-04 | — | — | US | disclosed |
| US-20130123241-A1 | NOVEL CCR2 RECEPTOR ANTAGONISTS, METHOD FOR PRODUCING THE SAME, AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123241-A1 | NOVEL CCR2 RECEPTOR ANTAGONISTS, METHOD FOR PRODUCING THE SAME, AND USE THEREOF AS MEDICAMENTS | CCR2, CXCR2, CYSLTR2 | CCR2 1/4885CCR5 5/4885LMNA 4590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.